CurrentAetnaPolicy 0593

Aerosolized or Irrigated Anti-infectives for Sinusitis

This policy governs the use and coverage stance for nasally aerosolized or irrigated anti-infective therapies for sinusitis for Aetna members.

Policy Summary

PayerAetna

PolicyAerosolized or Irrigated Anti-infectives for Sinusitis

Policy CodePolicy 0593

Change TypeNo material change

Effective DateMar 8, 2002

Next Review DateJun 27, 2024

Key ActionDo not authorize nasally aerosolized or irrigated anti-infectives for sinusitis; these uses are considered experimental/investigational and may be denied.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Experimental/Investigationalcoverage stance

No convincing RCT benefitRCTs outcome

10 trialsCochrane review

2002Policy year

06/27/2024Next review

Coverage Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Experimental/Investigational

Covered when ALL of the following are met:

Experimental/Investigational determination: Nasally aerosolized or irrigated anti-infectives are considered experimental and investigational for the treatment of sinusitis and other indications due to inadequate published clinical evidence of effectiveness.

Policy states lack of guideline support and limited data; use outside clearly established indications (e.g., cystic fibrosis or Pneumocystis pneumonia) should be exercised with caution.

This Clinical Policy Bulletin addresses the use of nasally aerosolized or irrigated anti-infectives for sinusitis. Professional guidance does not support routine use of these therapies for sinusitis, and the policy notes that such administration is considered experimental and investigational for treatment of sinusitis. Established indications for aerosolized antimicrobials — for example, treatment in patients with cystic fibrosis or Pneumocystis pneumonia — exist in other clinical contexts and are distinct from the sinusitis indication described here. Requests to use nasally aerosolized or irrigated anti-infectives for sinusitis fall outside those established indications and are subject to the policy’s investigational determination.

Randomized, placebo-controlled trials have not demonstrated convincing clinical benefit from adding nebulized or nasally irrigated antibiotics to saline or placebo in sinusitis. A randomized study by Desrosiers et al (2001) in 20 patients with chronic, refractory sinusitis found no clinically significant difference between nebulized tobramycin-saline solution and nebulized saline, leading the authors to conclude that the addition of tobramycin appears to be of minimal benefit.

A small randomized, double-blind, placebo-controlled crossover pilot study by Videler et al (2008) in 14 patients with recalcitrant chronic rhinosinusitis reported improvement in symptoms in both antibiotic and placebo (saline) arms, with no significant difference between bacitracin/colimycin and placebo. The investigators noted these small placebo-controlled studies consistently point to no effect from adding topical antibiotics and emphasized the need for larger randomized trials to draw definitive conclusions.

Coding and Billing

Other CPT codes related to the CPBCPT

94664	Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device.
99503	Home visit for respiratory therapy care (e.g., bronchodilator, oxygen therapy, respiratory assessment, apnea evaluation).

HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered

E0574	Ultrasonic/electronic aerosol generator with small volume nebulizer.
E0575	Nebulizer, ultrasonic, large volume.
E0580	Nebulizer, durable, glass or autoclavable plastic, bottle type, for use with regulator or flowmeter.
E0585	Nebulizer, with compressor and heater.

Other HCPCS codes related to the CPBHCPCS

A7013	Filter, disposable, used with aerosol compressor.
A7014	Filter, non-disposable, used with aerosol compressor or ultrasonic generator.
A7015	Aerosol mask, used with DME nebulizer.
E0572	Aerosol compressor, adjustable pressure, light duty for intermittent use.

ICD-10 codes referenced as not covered for indications listed in the CPBICD-10Not Covered

J01.00-J01.91	Acute sinusitis.
J32.0-J32.9	Chronic sinusitis.

Provider Responsibilities and Operational Guidance

Denial Risk

Experimental/Investigational — denial risk

Aetna considers nasally aerosolized or irrigated anti-infectives experimental and investigational for the treatment of sinusitis due to inadequate published clinical evidence of effectiveness. Requests to treat sinusitis with these approaches are at risk of denial.

Affected diagnoses: ICD-10 J01.00–J01.91 (Acute sinusitis); J32.0–J32.9 (Chronic sinusitis).
Related policy: CPB 0065 - Nebulizers.

Prior Authorization

Prior authorization — verify with payer

There are no specific prior authorization instructions provided in the referenced policy text. Providers should verify member-specific benefit coverage and any plan-level prior authorization requirements through the payer's standard authorization channels before initiating treatment.

Step Therapy

Therapy sequencing — conservative treatments first

Conservative therapies such as physiologic saline nasal irrigation and intranasal steroids (for CRS with polyposis) are supported by the literature; topical antimicrobials have limited/low-level evidence and should be considered only after standard therapies and culture-directed approaches when clinically appropriate.

Physiologic saline irrigation: supportive evidence for symptom relief.
Topical antibiotics: low-level evidence; culture-directed therapy preferred.

Documentation Required

Evidence limitations — documentation suggestions

Published studies are limited in size and quality (many uncontrolled, retrospective, or small randomized trials). Detailed clinical documentation should include indication, prior conservative treatments tried, culture results if topical antibiotics are considered, treatment regimen, and outcome measures.

Document prior systemic and topical therapies and duration.
Include culture-directed organism and sensitivity when topical antibiotics are used.
Record objective and patient-reported outcomes and duration of therapy.

Note

Provider responsibility — plan-level guidance only

This policy summary is a plan-level coverage determination. Treating providers are responsible for all medical advice, diagnosis, and treatment decisions. The Clinical Policy Bulletin is informational and does not replace individualized clinical judgment.

Background and Rationale

Nebulized and nasally irrigated anti-infectives have been proposed to deliver antibiotics or antifungals directly to the sinus mucosa to improve local concentrations and reduce systemic exposure. Proprietary devices and formulations such as the SinuNEB system and AdhesENT formulations are marketed to enhance deposition and medication adherence within the sinus cavities and claim improved effectiveness compared with systemic administration.

Published clinical evidence for these approaches is limited and consists mainly of uncontrolled case series, retrospective reviews, and small randomized trials. Manufacturer‑reported uncontrolled series suggested subjective improvement in some patients, but prospective randomized trials have not demonstrated consistent benefit. Leading professional guidelines do not recommend a role for nebulized or nasally irrigated antibiotics in routine sinusitis management, and the literature cautions that data are insufficient to support routine use outside clearly established indications (e.g., cystic fibrosis, Pneumocystis).

Because available studies are small and often nonrandomized, no firm conclusions about safety or effectiveness can be drawn for routine treatment of sinusitis with nebulized or nasally irrigated anti-infectives.

Definitions and Devices

SinuNEB / AdhesENT — device and proprietary formulation definition and manufacturer claims

DeviceSinuNEB — a device marketed by SinusPharmacy that nebulizes antibiotics, antifungals, and other medications for treatment of sinusitis.

Proprietary formulationAdhesENT — brand name for SinusPharmacy's unique formulations intended to increase medication adherence in the sinus cavities and improve delivery to the disease site.

Manufacturer claimsManufacturer states nebulized administration to the sinus lining provides more rapid response, greater effectiveness, reduced reinfection, and fewer side effects compared with oral or IV anti-infectives.

Evidence summaryManufacturer claims are not supported by sufficient published clinical studies; available uncontrolled and retrospective reports exist but lack prospective randomized data.

Randomized trial findingsA randomized clinical study (Desrosiers et al., 2001) found no clinically significant difference between nebulized tobramycin–saline and nebulized saline, suggesting minimal benefit of added antibiotic.

OpenPayer